ferrous-fumarate and Puerperal-Disorders

To evaluate the efficacy of adding folic acid to oral iron supplementation in postpartum women with anemia.. A randomized controlled trial was conducted in the Netherlands between April 8, 2008, and August 31, 2010. A total of 112 postpartum women with anemia (hemoglobin <10.5 g/dL) were randomly allocated to receive 600 mg/day ferrous fumarate plus 1mg/day folic acid (FFFA group) or 600/day ferrous fumarate alone (FF group) for 4 weeks. Primary outcome measures were hemoglobin and health status. Secondary outcome measures were fatigue, compliance, and adverse reactions.. No between-group differences were observed in hemoglobin and health status after treatment, and no differences were found in fatigue scores. Approximately 75% of all women reported having at least one symptom resulting from ferrous fumarate use. Constipation caused by ferrous fumarate was significantly associated with non-compliance (P=0.014).. The addition of folic acid to iron supplementation is not beneficial in women with postpartum anemia, as it has no effect on hematologic or health status parameters.. CCMO website NL21797.028.08 and Netherlands Trial Register NTR2232.

Topics: Adult; Anemia; Dietary Supplements; Drug Therapy, Combination; Female; Ferrous Compounds; Folic Acid; Health Status; Hemoglobins; Humans; Intention to Treat Analysis; Puerperal Disorders; Surveys and Questionnaires

Topics: Anemia; Blood Transfusion; Drug Therapy; Female; Ferrous Compounds; Humans; Iron; Pregnancy; Puerperal Disorders; Vitamins

Topics: Anemia; Anemia, Hypochromic; Anemia, Iron-Deficiency; Drug Therapy; Female; Ferrous Compounds; Fumarates; Humans; Iron; Postpartum Period; Pregnancy; Pregnancy Complications, Hematologic; Puerperal Disorders